IS Pharma portfolio development pays off
NORTH West pharmaceuticals group IS Pharma has announced full year profits and earnings will be ahead of expectations.
The Chester-based group said the focus for the year had been on growing earnings and developing the portfolio to drive long term profit growth.
Post tax profits and earnings per share materially will be ahead of expectations and in line on all other key parameters for the year to the end of March, it said in its trading update.
It said: “Significant steps have been taken over the year to further enhance the portfolio, in particular with the international launches of Variquel, acquisitions of patented, complementary brands Aequasyal (Aquoral) and Episil and the divestment of Volplex/Isoplex.”
IS Pharma added that it will focus on launching and growing the newer higher margin brands over the next year.
